Status:
COMPLETED
The Effect of Azithromycin Use on Conduction System of Heart in COVID-19 Positive Children
Lead Sponsor:
Kayseri City Hospital
Conditions:
Azithromycin Adverse Reaction
Covid19
Eligibility:
All Genders
1-18 years
Brief Summary
Azithromycin (AZ) is used in the pediatric group in COVID-19 diseas. It has been reported to cause prolongation in the QT interval in adult age group. The aim of this study is to evaluate the effect o...
Detailed Description
The study was prospectively conducted between June 2020 and August 2020. Children hospitalized in Kayseri City Hospital Pediatric Infection Clinic for coronavirus disease and receiving oral AZ treatme...
Eligibility Criteria
Inclusion
- PCR positive COVID-19 patients
- Age\<18 yearts
- Minimum 3 days oral Azithromycin therapy
- At least one ECG before and after treatment
Exclusion
- parasitic ECG
- not having at least 1 ECG before or after treatment
- taking drugs other than hydroxychloroquine to prolong the QT interval
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2020
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT04699097
Start Date
July 1 2020
End Date
November 1 2020
Last Update
January 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Süleyman Sunkak
Kayseri, In the USA Or Canada, Please Select..., Turkey (Türkiye), (554) 217-68